Brief: Polyphor Announces Progress Of Phase III Immuno-Oncology Program With Balixafortide

Spexis AG

20/02/2020 06:08

Feb 20 (Reuters) - POLYPHOR AG  POLN.S :
    * ANNOUNCES PROGRESS OF PHASE III IMMUNO-ONCOLOGY PROGRAM
WITH
BALIXAFORTIDE. RENEWED STRATEGY IN ADVANCING ANTIBIOTICS AND
ONCOLOGY RESEARCH AND PIPELINE
    * RECONFIRMS ITS GUIDANCE THAT WITH EXISTING CASH,
OPERATIONS ARE
FINANCED UNTIL END OF Q1 2021
    * CASH POSITION TO ALLOW POLYPHOR TO DEVELOP BALIXAFORTIDE
PROGRAM
TOWARDS NEXT VALUE INFLECTION POINT (ORR, AROUND END OF Q1 2021)

Source text for Eikon:  ID:nEQ3B8qJWa 
Further company coverage:  POLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))